Effects of subclass change on the structural stability of chimeric, humanized, and human antibodies under thermal stress

Protein Science

Volumn 22, Issue 11, 2013, Pages 1542-1551

  Ito, Takahiko ^a,b   Tsumoto, Kouhei ^a,b  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Antibody; Circular dichroism; Differential scanning calorimetry; Differential scanning fluoroscopy; Subclass change; Thermodynamic stability

Indexed keywords

IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G4; MONOCLONAL ANTIBODY;

ANTIBODY STRUCTURE; ARTICLE; CIRCULAR DICHROISM; CONFORMATIONAL TRANSITION; DIFFERENTIAL SCANNING CALORIMETRY; DIFFERENTIAL SCANNING FLUOROSCOPY; FLUOROSCOPY; GEL PERMEATION CHROMATOGRAPHY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN STABILITY; TEMPERATURE STRESS; THERMODYNAMICS;

ANTIBODY; CIRCULAR DICHROISM; DIFFERENTIAL SCANNING CALORIMETRY; DIFFERENTIAL SCANNING FLUOROSCOPY; SUBCLASS CHANGE; THERMODYNAMIC STABILITY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CALORIMETRY, DIFFERENTIAL SCANNING; CHO CELLS; CHROMATOGRAPHY, GEL; CIRCULAR DICHROISM; CRICETULUS; FLUORESCENT DYES; FLUOROSCOPY; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN VARIABLE REGION; PROTEIN STABILITY; PROTEIN STRUCTURE, SECONDARY; RECOMBINANT FUSION PROTEINS; REPRODUCIBILITY OF RESULTS; STRESS, PHYSIOLOGICAL; TEMPERATURE; THERMODYNAMICS;

EID: 84892369713     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1002/pro.2340     Document Type: Article

References (47)

1. Chan AC, Carter PJ (2010) Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 10: 301-316.
2. Beck A, Wurch T, Bailly C, Corvaia N (2010) Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 10:345-352.
3. Reichert JM (2012) Marketed therapeutic antibodies compendium. mAbs 4:413-415.
4. Davies DR, Metzger H (1983) Structural basis of antibody function. Annu Rev Immunol 1:87-117.
5. Cambier JC, Bedzyk W, Campbell K, Chien N, Friedrich J, Harwood A, Jensen W, Pleiman C, Clark MR (1993) The B-Cell antigen receptor: structure and function of primary, secondary, tertiary and quaternary components. Immunol Rev 132:85-106.
6. Jefferis R (2007) Antibody therapeutics: isotype and glycoform selection. Exp Opin Biol Ther 7:1401-1413.
7. Clark MR (1997) IgG effector mechanism. Chem Immunol 7:715-725.
8. Bell E (2006) Antibodies: IgG effector function: a question of balance. Nat Rev Immunol 6:4-5.
9. Salfeld JG (2007) Isotype selection in antibody engineering. Nat Biotechnol 25:1369-1372.
10. Labrijn AF, Aalberse RC, Schuurman J (2008) When binding is enough: nonactivating antibody formats. Curr Opin Immunol 20:479-485.
11. Jiang XR, Song A, Bergelson S, Arroll T, Parekh B, May K, Chung S, Strouse R, Mire-Sluis A, Schenerman M (2011) Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov 10:101-109.
12. Dall'Acqua WF, Cook KE, Damschroder MM, Woods RM, Wu H (2006) Modulation of the effector functions of a human IgG1 through engineering of its hinge region. J Immunol 177:1129-1138.
13. Yoo EM, Wims LA, Chan LA, Morrison SL (2003) Human IgG2 can form covalent dimers. J Immunol 170:3134-3138.
14. Wypych J, Li M, Guo A, Zhang Z, Martinez T, Allen MJ, Fodor S, Kelner DN, Flynn GC, Liu YD, Bondarenko PV, Ricci MS, Dillon TM, Balland A (2008) Human IgG2 antibodies display disulfide-mediated structural isoforms. J Biol Chem 283:16194-16205.
15. Dillon TM, Ricci MS, Vezina C, Flynn GC, Liu YD, Rehder DS, Plant M, Henkle B, Li Y, Deechongkit S, Varnum B, Wypych J, Balland A, Bondarenko PV (2008) Structural and functional characterization of disulfide isoforms of the human IgG2 subclass. J Biol Chem 283:16206-16215.
16. Liu YD, Chen X, Enk JZ, Plant M, Dillon TM, Flynn GC (2008) Human IgG2 antibody disulfide rearrangement in vivo. J Biol Chem 283:29266-29272.
17. Martinez T, Guo A, Allen MJ, Han M, Pace D, Jones J, Gillespie R, Ketchem RR, Zhang Y, Balland A (2008) Disulfide connectivity of human immunoglobulin G2 structural isoforms. Biochemistry 47:7496-7508.
18. Van der Neut Kolfxchoten M, Schuurman J, Losen M, Bleeker WK, Martinez-Martinez P, Vermeulen E, den Bleker TH, Wiegman L, Vink T, Aarden LA, De Baets MH, van de Winkel JG, Aalberse RC, Parren PW (2007) Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317: 1554-1557.
19. Van der Zee JS, van Swieten P, Aalberse RC (1986) Serologic aspects of IgG4 antibodies. IgG4 antibodies form small, nonprecipitating immune complexes due to functional monovalency. J Immunol 137:3566-3571.
20. Schuurman J, Van Ree R, Perdok GJ, Van Doorn HR, Tan KY, Aalberse RC (1997) Normal human immunogloblin G4 is bispecific: it has two different antigencombining sites. Immunology 97:693-698.
21. Ejima D, Tsumoto K, Fukuda H, Yumioka R, Nagase K, Arakawa T, Philo JS (2007) Effects of acid exposure on the conformation, stability, and aggregation of monoclonal antibodies. Proteins 66:954-962.
22. Franey H, Brych SR, Kolvenbach CG, Rajan RS (2010) Increased aggregation propensity of IgG2 subclass over IgG1: role of conformational changes and covalent character in isolated aggregates. Protein Sci 19:1601-1615.
23. Vermeer AW, Norder W (2000) The thermal stability of immunoglobulin: unfolding and aggregation of a multidomain protein. Biophys J 78:394-404.
24. Garber E, Demarest JD (2007) A broad range of Fab stabilities within a host of therapeutic IgGs. Biochem Biophys Res Commun 355:751-757.
25. Demarest SJ, Rogers J, Hansen G (2004) Optimization of the antibody CH3 domain by residue frequency analysis of IgG sequences. J Mol Biol 335:41-48.
26. Hari SB, Lau H, Razinkov VI, Chen S, Latypov RF (2010) Acid-induced aggregation of human monoclonal IgG1 and IgG2: molecular mechanism and the effect of solution composition. Biochemistry 49:9328-9338.
27. Latypov RF, Hogan S, Lau H, Gadgil H, Liu D (2012) Elucidation of acid-induced unfolding and aggregation of human immunoglobulin IgG1 and IgG2 Fc. J Biol Chem 287:1381-1396.
28. Andersen CB, Manno M, Rischel C, Thorolfsson M, Martorana V (2010) Aggregation of multidomain protein: a coagulation mechanism governs aggregation of a model IgG1 antibody under weak thermal stress. Protein Sci 19:279-290.
29. He F, Hogan S, Latypov RF, Narhi LO, Razinkov VI (2010) High throughput thermostability screening of monoclonal antibody formulations. J Pharm Sci 99: 1707-1720.
30. Goldberg DS, Bishop SM, Shah AU, Sathish HA (2010) Formulation development of therapeutic monoclonal antibodies using high-throughput fluorescence and static light scattering techniques: role of conformational and colloidal stability. J Pharm Sci 100:1306-1315.
31. King AC, Woods M, Liu W, Lu Z, Gill D, Krebs MR (2011) High-throughput measurement, correlation analysis, and machine-learning predictions for pH and thermal stabilities of Pfizer-generated antibodies. Protein Sci 20:1546-1557.
32. Cohen SL, Price C, Vlasak J (2007) Beta-elimination and peptide bond hydrolysis: two distinct mechanisms of human IgG1 hinge fragmentation upon storage. J Am Chem Soc 129:6976-6977.
33. Xiang T, Lundell E, Sun Z, Liu H (2007) Structural effect of a recombinant monoclonal antibody on hinge region peptide bond hydrolysis. J Chromatogr 858:254-262.
34. Cordoba AJ, Shyong BJ, Breen D, Harris RJ (2005) Non-Enzymatic hinge region fragmentation of antibodies in solution. J Chromatogr 818:115-121.
35. Gaza-Bulseco G, Liu H (2008) Fragmentation of a recombinant monoclonal antibody at various pH. Pharm Res 25:1881-1890.
36. Ishikawa T, Ito T, Endo R, Nakagawa K, Sawa E, Wakamatsu K (2010) Influence of pH on heat-induced aggregation and degradation of therapeutic monoclonal antibodies. Biol Pharm Bull 33:1413-1417.
37. Franey H, Brych SR, Kolvenbach CG, Rajan RS (2010) Increased aggregation propensity of IgG2 subclass over IgG1: role of conformational change and covalent character in isolated aggregates. Protein Sci 19:1601-1615.
38. Daugherty AL, Mrsny RJ (2006) Formulation and delivery issue for monoclonal antibody therapeutics. Adv Drug Deliv Rev 58:686-706.
39. Fradkin AH, Carpenter JF, Randolph TW (2009) Immunogenicity of aggregates of recombinant human growth hormone in mouse models. J Pharm Sci 98: 3247-3264.
40. Rosenberg AS (2006) Effects of protein aggregates: an immunologic perspective. AAPS J 8:E501-E507.
41. Ionescu RM, Vlasak J, Price C, Kirchmeier M (2008) Contribution of variable domain to the stability of humanized IgG1 monoclonal antibodies. J Pharm Sci 97:1414-1426.
42. Welfle K, Misselwitz R, Hausdorf G, Höhne W, Welfle H (1999) Conformation, pH-induced conformational changes, and thermal unfolding of anti p24 (HIV-1) monoclonal antibody CB 4-1 and its Fab and Fc fragments. Biochim Biophys Acta 1431:120-131.
43. Angal S, King DJ, Bodmer MW, Turner A, Lawson AD, Roberts G, Pedley B, Adair JR (1993) A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol Immunol 30: 105-108.
44. Reddy MP, Kinney CA, Chaikin MA, Payne A, Fishman-Lobell J, Tsui P, Dal Monte PR, Doyle ML, Brigham-Burke MR, Anderson D, Reff M, Newman R, Hanna N, Sweet RW, Truneh A (2000) Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4. J Immunol 164:1925-1933.
45. Cole MS, Anasetti C, Tso JY (1997) Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells. J Immunol 159:3613-3621.
46. Oganesyan V, Gao C, Shirinian L, Wu H, Dall'Acqua WF (2008) Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Cryst D64:700-704.
47. An Z, Forrest G, Moore R, Cukan M, Haytko P, Huang L, Vitelli S, Zhao JZ, Lu P, Hua J, Gibson CR, Harvey BR, Montgomery D, Zaller D, Wang F, Strohl W (2009) IgG2m4, an engineered antibody isotype with reduced Fc function. Mabs 1:572-579.